Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:3:p1
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 3 (pt 1/8)
Character Range: 160627–163502

Schedule 3—Pharmacist only medicines

Note: See sections 16 and 31, subsections 54(2) and 57(1) and section 59.
ADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age.
ADRENALINE in preparations containing 1% or less of adrenaline except in preparations that are not for injection containing 0.02% or less of adrenaline.
ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or less of the preparation.
ALIMEMAZINE:
 (a) in solid oral preparations except when included in Schedule 2; or
 (b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL;
 except in preparations for the treatment of children under 2 years of age.
AMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline.
AMYL NITRITE when in preparations for human therapeutic use and packaged in containers with child‑resistant closures.
ASTODRIMER SODIUM except:

       (a) when included in Schedule 2; or

       (b) in a condom lubricant.
AZATADINE in oral preparations.
BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 10 mg of bilastine for the treatment of children 6-11 years of age except when included in Schedule 2.
BROMPHENIRAMINE in oral preparations except:
 (a) when included in Schedule 2; or
 (b) for the treatment of children under 2 years of age.
BUCLIZINE in oral preparations.
BUTOCONAZOLE in preparations for vaginal use.
CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when:
 (a) the cannabidiol is either plant derived or, when synthetic, only contains the (‑)‑CBD enantiomer; and
 (b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and
 (c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and
 (d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and
 (e) packed in blister or strip packaging or in a container fitted with a child‑resistant closure; and
 (f) in packs containing not more than 30 days' supply; and
 (g) for persons aged 18 years and over.
CELECOXIB in tablets or capsules each containing 200 mg or less of celecoxib, in a primary pack containing not more than 10 dosage units for the short‑term treatment of acute pain due to primary dysmenorrhea or musculoskeletal or soft tissue injuries in adults.
CHLORAMPHENICOL for ophthalmic use only.
CHLORBUTANOL in preparations for human use except:
 (a) when included in Schedule 2; or
 (b) in preparations containing 0.5% or